Everything below concerns fatty diacid chain. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-24. Numbers and descriptions here follow the published literature rather than marketing material.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Acylated GLP-1 receptor agonist | 31-residue synthetic peptide |
| Molecular formula | C187H291N45O59 | established for the free peptide |
| Appearance | White to off-white powder | as supplied before formulation |
| Solubility | Freely soluble in water | aqueous buffers near neutral pH |
| Typical storage | 2 to 8 degrees Celsius, protected from light | powder and solution forms differ in shelf life |
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
=== Worms === The microscopic soil-dwelling nematode roundworms Panagrolaimus detritophagus and Plectus parvus are the only eukaryotic organisms that have been proven to be viable after cryopreservation for many years (30,000 to 40,000 years). In this case, the preservation was natural rather than artificial, due to permafrost. They came alive when warmed up.
== Ideology == The Truth and Reconciliation Commission described the BBB's ideology as "refined nazism". Schabort himself described the organisation as "openly racist". It was white supremacist and against race mixing. The BBB regarded blacks as 'mud people' or 'mud race'. The BBB sought the 'repatriation' (expulsion) of blacks from South Africa, "by violence if necessary". It was openly antisemitic, regarding Jews as existing between white and blacks, and denied the Holocaust. The BBB was against democracy and sought a new economic order. The AWB criticised the BBB for being anti-Christian and atheistic; the BBB's tendency was towards the Church of the Creator. The BBB used the winged variant of the Odal SS-rune as its symbol.
replisome The entire complex of molecular machinery that carries out the process of DNA replication, including all proteins, nucleic acids, and other molecules which participate at an active replication fork.
In microfluidics, MHD is studied as a fluid pump for producing continuous, nonpulsating flow in a complex microchannel design. MHD can be implemented in the continuous casting of metals to suppress instabilities and control flow. Industrial MHD problems can be modeled using the open-source software EOF-Library. Two simulation examples are three-dimensional MHD with a free surface for electromagnetic levitation melting and liquid-metal stirring using rotating permanent magnets.
Sources: en.wikipedia.org
The periodic table is a graphic description of the periodic law, which states that the properties and atomic structures of the chemical elements are a periodic function of their atomic number. Elements are placed in the periodic table according to their electron configurations, the periodic recurrences of which explain the trends in properties across the periodic table. An electron can be thought of as inhabiting an atomic orbital, which characterizes the probability it can be found in any particular region around the atom. Their energies are quantised, which is to say that they can only take discrete values. Furthermore, electrons obey the Pauli exclusion principle: different electrons must always be in different states. This allows classification of the possible states an electron can take in various energy levels known as shells, divided into individual subshells, which each contain one or more orbitals. Each orbital can contain up to two electrons: they are distinguished by a quantity known as spin, conventionally labelled "up" or "down". In a cold atom (one in its ground state), electrons arrange themselves in such a way that the total energy they have is minimized by occupying the lowest-energy orbitals available. Only the outermost electrons (valence electrons) have enough energy to break free of the nucleus and participate in chemical reactions with other atoms. The others are called core electrons.
Cuprate of Tl–Ba–Ca The first series of the Tl-based superconductor containing one Tl–O layer has the general formula TlBa2Can−1CunO2n+3, whereas the second series containing two Tl–O layers has a formula of Tl2Ba2Can−1CunO2n+4 with n =1, 2 and 3. In the structure of Tl2Ba2CuO6 (Tl-2201), there is one CuO2 layer with the stacking sequence (Tl–O) (Tl–O) (Ba–O) (Cu–O) (Ba–O) (Tl–O) (Tl–O). In Tl2Ba2CaCu2O8 (Tl-2212), there are two Cu–O layers with a Ca layer in between. Similar to the Tl2Ba2CuO6 structure, Tl–O layers are present outside the Ba–O layers. In Tl2Ba2Ca2Cu3O10 (Tl-2223), there are three CuO2 layers enclosing Ca layers between each of these. In Tl-based superconductors, Tc is found to increase with the increase in CuO2 layers. However, the value of Tc decreases after four CuO2 layers in TlBa2Can−1CunO2n+3, and in the Tl2Ba2Can−1CunO2n+4 compound, it decreases after three CuO2 layers. Cuprate of Hg–Ba–Ca The crystal structure of HgBa2CuO4 (Hg-1201), HgBa2CaCu2O6 (Hg-1212) and HgBa2Ca2Cu3O8 (Hg-1223) is similar to that of Tl-1201, Tl-1212 and Tl-1223, with Hg in place of Tl. It is noteworthy that the Tc of the Hg compound (Hg-1201) containing one CuO2 layer is much larger as compared to the one-CuO2-layer compound of thallium (Tl-1201). In the Hg-based superconductor, Tc is also found to increase as the CuO2 layer increases. For Hg-1201, Hg-1212 and Hg-1223, the values of Tc are 94, 128, and the record value at ambient pressure 134 K (−139 °C), respectively, as shown in table below.
It is chemically designated in International Union of Pure and Applied Chemistry (IUPAC) nomenclature as 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]benzamide monohydrochloride. The experimental log P of labetalol is 2.7 to 3.1 and its predicted log P ranges from 1.73 to 3.1. Hence, it has relatively high lipophilicity.
Sources: en.wikipedia.org
Ginkgotoxin (4'-O-methylpyridoxine) is a neurotoxin naturally occurring in Ginkgo biloba. It is an antivitamin structurally related to vitamin B6 (pyridoxine). It has the capacity to induce epileptic seizures.
=== Organic compound peptide-based batteries === StoreDot reported in 2014 to have developed organic-compound peptide-based smartphone batteries capable of being fully charged within 30 seconds. The company said its 30-second-charging organic-compound-based battery would be commercially available for smartphones by 2016. The company announced its 5-minutes-to-full-charge organic batteries will be available for 300-mile-range electric vehicles and aerial drones by 2020. The company acknowledged in 2015 that its claims regarding its organic batteries have not been scientifically peer-reviewed.
Siddhartha Roy (born 1 April 1954) is an Indian Chemical and Structural biologist, biophysicist, former director of the Indian Institute of Chemical Biology and the former director (officiating) of Bose Institute. Widely known for his studies on Gene Regulation, Peptidomimetics, bacteriophage lambda and protein synthesis, he is an elected fellow of the Indian Academy of Sciences and the Indian National Science Academy. In 1999, the Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, for his contributions to Biological sciences.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.
The fatty diacid chain associates strongly with serum albumin, which keeps the peptide in circulation and shields it from rapid renal clearance. Bound peptide is released gradually, producing a sustained receptor signal. This mechanism also reduces the peak-to-trough variation seen with shorter-acting analogues.
The balance between peripheral receptor activation and signalling in the central nervous system is not fully resolved. The extent to which slowed gastric emptying accounts for reduced energy intake, compared with direct effects on appetite circuits, is debated. Long-term effects on lean mass and on tissues outside the gut and brain are still under study.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.